Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity.
about
PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract.A phase I dose escalation study of oxaliplatin plus oral S-1 and pelvic radiation in patients with locally advanced rectal cancer (SHOGUN trial).Dose-finding study on adjuvant chemotherapy with S-1 plus oxaliplatin for gastric cancer.A phase II study of preoperative chemoradiation with tegafur-uracil plus leucovorin for locally advanced rectal cancer with pharmacogenetic analysisS-1 as a core anticancer fluoropyrimidine agent.Chemotherapy for the biliary tract cancers: moving toward improved survival time.Signaling pathways as therapeutic targets in biliary tract cancer.Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients.Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.Variation in CYP2A6 Activity and Personalized Medicine.
P2860
Q27012807-6F11709A-E86E-44D3-BBB0-BD87986A3C84Q33430668-27206192-0C88-4367-B513-C6C8FB5BEBF7Q35033392-C686E67E-3E83-47F2-BA08-DDC283731D33Q37561374-F019854D-97EA-4832-A8CA-9779174CFF10Q37724706-8CF31200-BA86-403F-B12F-D46A69CBE2E0Q37974935-B3449B7A-DC1B-475C-8682-9016F1D7ACDCQ37983498-555E899E-BB69-4EC7-BF66-DA08C0695364Q38747573-7C9A40B5-B610-45B2-B97B-880237DEECF6Q39566084-BBDD18CD-90C6-4F4E-9687-13F9ABF8EF4AQ44150769-19007AE5-B645-47F3-8F01-1687F4C8EB97Q47163198-950A97F9-B643-4C5E-83F4-1095EC42B024
P2860
Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Phase II study of S-1 combined ...... inetics and clinical activity.
@ast
Phase II study of S-1 combined ...... inetics and clinical activity.
@en
Phase II study of S-1 combined ...... inetics and clinical activity.
@nl
type
label
Phase II study of S-1 combined ...... inetics and clinical activity.
@ast
Phase II study of S-1 combined ...... inetics and clinical activity.
@en
Phase II study of S-1 combined ...... inetics and clinical activity.
@nl
prefLabel
Phase II study of S-1 combined ...... inetics and clinical activity.
@ast
Phase II study of S-1 combined ...... inetics and clinical activity.
@en
Phase II study of S-1 combined ...... inetics and clinical activity.
@nl
P2093
P2860
P356
P1476
Phase II study of S-1 combined ...... inetics and clinical activity.
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.2011.17
P407
P577
2011-02-01T00:00:00Z
P5875
P6179
1044516624